SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 199.20+0.1%Nov 21 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Spekulatius who wrote (22063)6/11/1998 8:33:00 AM
From: jayhawk969  Read Replies (2) of 32384
 


<Someone on this thread brought up a very important point - the
issue of stock,or stock dilution. If you look at the number from
wsrn easily accessible from SI, you will see, that the # of stocks
from 94 till now has increased from about 19Mill to 39 Mill
shares. This is an tremendous dilution of stock even for a biotech.
LGND has racked up 100M$ of losses in the last two years...all
financed by new share issues.
In my opinion this lack of consciousness for shareholder value is
the reason for the low share price. My opinion is,that marketing a
new drug, like ONTAK or Panretin will even increase capital
requirements, before a positive cash flow can be
established,which will force further dilution in the near future.
Nobody here in this thread questions the quality of LGND's
research but more consciousness about shareholders value would
help the stock more than another alliance or another research
project...>

Whick programs would you have cut or what alternative mechanisms of finance would you have used? Or what other alternatives do you have for the increase in shareholder value when you are trying to build a company that does not yet have a product?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext